January 26, 2021
Chugai Pharmaceutical said on January 25 that it has earned approval for the label expansion of FoundationOne CDx Cancer Genomic Profile as a companion diagnostic for Bayer Yakuhin’s TRK inhibitor larotrectinib. FoundationOne is now approved to detect mutations for larotrectinib,...read more